{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Steroids: treatment initiated at least 3 months prior to Screening and no dose', 'changes in the last month before Screening.', 'Acetylcholinesterase inhibitors: stable dose with no dose escalation in the past', '2 weeks before Screening.', 'Note: AChE inhibitors must be halted for at least 12 hours consistent with the', 'revised manual for the QMG test as recommended by the MGFA, before the', 'QMG assessment.', '4.3.2.', 'Exclusion Criteria', 'Patients will not be randomized in this trial if they meet any of the following criteria:', '1.', 'Pregnant and lactating women, and those intending to become pregnant during the trial', 'or within 90 days after the last dosing. Women of childbearing potential (see', 'DEFINITION OF TERMS) should have a negative serum pregnancy test at Screening', 'and a negative urine pregnancy test at Baseline (SEB) prior to administration of IMP.', 'Note: Women of childbearing potential should use a highly effective method of', 'contraception (i.e., pregnancy rate of less than 1% per year) during the trial and for', '90 days after the last administration of the IMP. They must be on a stable regimen, for', 'at least 1 month, of combined estrogen and progestogen hormonal contraception with', 'inhibition of ovulation, progestogen-only hormonal contraception associated with', 'inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing', 'system, bilateral tubal occlusion, vasectomized partner, or agree upon continuous', 'abstinence from heterosexual sexual contact.', '2.', 'Male patients who are sexually active and do not intend to use effective methods of', 'contraception (as mentioned above) during the trial or within 90 days after the last', 'dosing or male patients who plan to donate sperm during the trial or within 90 days', 'after the last dosing.', 'Note: Sterilized male patients who have had vasectomy with documented aspermia', 'post-procedure, or male patients who have a partner of non-childbearing potential, can', 'be included.', '3.', 'MGFA Class I and V patients.', '4.', 'Patients with worsening muscle weakness secondary to concurrent infections or', 'medications (aminoglycosides, fluoroquinolones, beta-blockers, etc.).', '5.', 'Patients with known seropositivity or who test positive for an active viral infection at', 'Screening with:', 'Hepatitis B Virus (HBV) (except patients who are seropositive because of HBV', 'vaccination)', 'argenx BVBA', 'Confidential', 'Page 57 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Hepatitis C Virus (HCV)', 'Human Immunodeficiency Virus (HIV)', '6.', 'Patients with any known severe bacterial, viral or fungal infection or any major episode', 'of infection that required hospitalization or injectable antimicrobial therapy in the last', '8 weeks prior to Screening.', '7.', 'Patients with known autoimmune disease other than MG (for example autoimmune', 'thyroiditis, rheumatoid arthritis ) that would interfere with an accurate assessment of', 'clinical symptoms.', '8.', 'Patients with total IgG level < 6 g/L at Screening.', '9.', 'Patients with documentation of a lack of clinical response to PLEX.', '10.', 'Use of investigational drug within 3 months or 5 half-lives of the drug (whichever is', 'longer) prior to Screening.', '11. Immunoglobulins given by IV (IVIg), subcutaneous or intramuscular route, or PLEX,', 'each within 1 month prior to Screening.', '12. Patients who have a history of malignancy, including malignant thymoma, or', 'myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate', 'treatment with no evidence of recurrence for > 3 years before Screening. Patients with', 'completely excised non-melanoma skin cancer (such as basal cell carcinoma or', 'squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.', '13. Thymectomy when performed < 3 months prior to Screening or planned to be', 'performed during the trial period.', '14. Patients with clinical evidence of other significant serious disease or patients who', 'underwent a recent major surgery, which could confound the results of the trial or put', 'the patient at undue risk. Patients with renal/hepatic function impairment can be', 'included.', '15.', 'Patients who previously participated in a clinical trial with ARGX-113.', '16.', 'Patients who received a vaccination (e.g., influenza vaccine) within the last 4 weeks prior', 'to Screening.', '17.', 'Use of any monoclonal antibody, such as rituximab and eculizumab, within 6 months', 'prior to first dosing.', '4.4.', 'Early Discontinuation', 'The criteria for screening and randomization are to be followed explicitly. If it is noted that a', 'patient who does not meet one or more of the inclusion and/or meets one or more of the', 'argenx BVBA', 'Confidential', 'Page 58 of 110']\n\n###\n\n", "completion": "END"}